

Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

[Home](#)³ [News & Events](#)⁴ [Newsroom](#)⁵ [Press Announcements](#)⁶

News & Events

FDA NEWS RELEASE

For Immediate Release: Dec. 26, 2012

Media Inquiries: Stephanie Yao, 301-796-0394, stephanie.yao@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

FDA approves new orphan drug for rare cholesterol disorder

On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Juxtapid is intended for use in combination with a low fat diet and other lipid-lowering treatments.

HoFH is a rare inherited condition that makes the body unable to remove LDL cholesterol, often called the “bad” cholesterol, from the blood, causing abnormally high levels of circulating LDL cholesterol. In the United States, HoFH occurs in approximately one in one million individuals. For those with HoFH, heart attacks and death often occur before age 30. Juxtapid works by impairing the creation of the lipid particles that ultimately give rise to LDL.

Juxtapid is a capsule taken once a day, without food, and at least two hours after the evening meal. Patients should take supplements that contain fat-soluble vitamins and essential fatty acids daily while taking Juxtapid.

“Juxtapid, in addition to diet changes and other cholesterol-lowering treatments, is a new option for those suffering with HoFH and the serious health consequences resulting from this condition,” said Eric Colman, M.D., deputy director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research.

The safety and effectiveness of Juxtapid were evaluated in a clinical trial of 29 patients with HoFH. On average, levels of LDL cholesterol fell by approximately one-half during the first 26 weeks among those who tolerated the drug. Juxtapid carries a Boxed Warning regarding a serious risk of liver toxicity because it is associated with liver enzyme abnormalities and accumulation of fat in the liver, which could potentially lead to progressive liver disease with chronic use. Juxtapid also reduces the absorption of fat-soluble nutrients and interacts with several other medications.

The FDA approved Juxtapid with a Risk Evaluation and Mitigation Strategy (REMS) that consists of elements to ensure safe use including prescriber and pharmacy certification and documentation of safe-use conditions consisting of a prescription authorization form that will be required to accompany each new prescription.

The FDA is requiring three postmarketing studies for Juxtapid: an animal study to evaluate the potential for toxicity in children and teens; a long-term registry of patients with HoFH treated with Juxtapid to determine the long-term safety; and an enhanced pharmacovigilance program to monitor reports of malignancy, teratogenicity, and hepatic abnormalities.

The most common adverse reactions in the clinical trial included diarrhea, nausea, vomiting, indigestion, and abdominal pain.

Juxtapid is marketed by Cambridge, Mass.-based Aegerion Pharmaceuticals Inc.

For more information:

[FDA Approved Drugs](#)¹¹

[FDA: Drug Innovation](#)¹²

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

#

Read our Blog: [FDA Voice](#)¹³

Page 1 of 2

Visit the FDA on [Facebook](#)¹⁴, [Flickr](#)¹⁵, [YouTube](#)¹⁶ and [Twitter](#)¹⁷¹⁸

RSS Feed for [FDA News Releases](#)¹⁹

Page Last Updated: 12/26/2012

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact FDA Careers FDA Basics FOIA No FEAR Act Site Map Transparency Website Policies](#)

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)

[Contact FDA](#)



[For Government For Press](#)

[Combination Products Advisory Committees Science & Research Regulatory Information Safety Emergency Preparedness International Programs News & Events Training and Continuing Education Inspections/Compliance State & Local Officials Consumers Industry Health Professionals FDA Archive](#)



U.S. Department of **Health & Human Services**

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdomain>
2. <http://www.addthis.com/bookmark.php>
3. </default.htm>
4. </NewsEvents/default.htm>
5. </NewsEvents/Newsroom/default.htm>
6. </NewsEvents/Newsroom/PressAnnouncements/default.htm>
7. </NewsEvents/Newsroom/default.htm>
8. </NewsEvents/Newsroom/PressAnnouncements/default.htm>
9. </NewsEvents/Newsroom/PressAnnouncements/2014/default.htm>
10. </NewsEvents/Newsroom/PressAnnouncements/2013/default.htm>
11. </Drugs/ResourcesForYou/Consumers/ucm054420.htm>
12. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/default.htm>
13. <https://blogs.fda.gov/fdavoice/>
14. <http://www.facebook.com/FDA>
15. <http://www.flickr.com/photos/fdaphotos/>
16. <http://www.youtube.com/user/USFoodandDrugAdmin?blend=23&ob=5>
17. http://twitter.com/us_fda
18. <http://www.fda.gov/AboutFDA/AboutThisWebsite/WebsitePolicies/Disclaimers/default.htm>
19. <http://www.fda.gov/AboutFDA/ContactFDA/StayInformed/RSSFeeds/PressReleases/rss.xml>